JP2024510249A - 神経疾患を治療するための組成物およびその方法 - Google Patents
神経疾患を治療するための組成物およびその方法 Download PDFInfo
- Publication number
- JP2024510249A JP2024510249A JP2023556900A JP2023556900A JP2024510249A JP 2024510249 A JP2024510249 A JP 2024510249A JP 2023556900 A JP2023556900 A JP 2023556900A JP 2023556900 A JP2023556900 A JP 2023556900A JP 2024510249 A JP2024510249 A JP 2024510249A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- group
- pharmaceutically acceptable
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163163546P | 2021-03-19 | 2021-03-19 | |
| US63/163,546 | 2021-03-19 | ||
| PCT/US2022/020687 WO2022197885A1 (en) | 2021-03-19 | 2022-03-17 | Compositions and methods for treating neurologic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024510249A true JP2024510249A (ja) | 2024-03-06 |
| JP2024510249A5 JP2024510249A5 (cg-RX-API-DMAC7.html) | 2025-03-26 |
Family
ID=83320987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023556900A Pending JP2024510249A (ja) | 2021-03-19 | 2022-03-17 | 神経疾患を治療するための組成物およびその方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240165077A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4308565A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024510249A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230159546A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117355525A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022239497A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3212092A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL306063A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023010831A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022197885A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117945980A (zh) * | 2024-01-24 | 2024-04-30 | 上海健康医学院 | 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用 |
| WO2026064542A1 (en) * | 2024-09-18 | 2026-03-26 | Cognition Therapeutics, Inc. | 2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol fumarate salts in solid forms |
| WO2026119142A1 (zh) * | 2024-12-03 | 2026-06-11 | 浙江径科医药有限公司 | 一种氘代异吲哚啉化合物及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018156883A1 (en) * | 2017-02-23 | 2018-08-30 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1294358B1 (en) | 2000-06-28 | 2004-08-18 | Smithkline Beecham Plc | Wet milling process |
| WO2013029057A2 (en) * | 2011-08-25 | 2013-02-28 | Cognition Therapeutics, Inc. | Compositions and methods for treating neurodegenerative disease |
| WO2015116923A1 (en) * | 2014-01-31 | 2015-08-06 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| ES3063712T3 (en) * | 2017-05-15 | 2026-04-20 | Cognition Therapeutics Inc | Compositions for treating neurodegenerative diseases |
| US20200338045A1 (en) * | 2017-11-01 | 2020-10-29 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| JP2022537581A (ja) * | 2019-06-21 | 2022-08-26 | クラリス コーポレーション | Ppm1阻害剤およびその使用方法 |
| CN110283082A (zh) * | 2019-07-15 | 2019-09-27 | 泰州职业技术学院 | 一种3-苯基丙胺的制备方法 |
-
2022
- 2022-03-17 CA CA3212092A patent/CA3212092A1/en active Pending
- 2022-03-17 US US18/280,565 patent/US20240165077A1/en not_active Abandoned
- 2022-03-17 MX MX2023010831A patent/MX2023010831A/es unknown
- 2022-03-17 EP EP22772183.4A patent/EP4308565A4/en active Pending
- 2022-03-17 JP JP2023556900A patent/JP2024510249A/ja active Pending
- 2022-03-17 CN CN202280035073.7A patent/CN117355525A/zh active Pending
- 2022-03-17 WO PCT/US2022/020687 patent/WO2022197885A1/en not_active Ceased
- 2022-03-17 KR KR1020237035979A patent/KR20230159546A/ko active Pending
- 2022-03-17 AU AU2022239497A patent/AU2022239497A1/en active Pending
- 2022-03-17 IL IL306063A patent/IL306063A/en unknown
-
2026
- 2026-02-04 US US19/529,760 patent/US20260166006A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018156883A1 (en) * | 2017-02-23 | 2018-08-30 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
Non-Patent Citations (3)
| Title |
|---|
| "Cognition Therapeutics Receives $6.6M in NIA Grants for Two Studies of ElaytaTM to Expand Understand", COGNITION THERAPEUTICS, INC プレスリリース, JPN6026013613, 2018, ISSN: 0005834535 * |
| CASTELLS, X. ET AL.: "Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults", COCHRANE DATABASE OF SYSTEMATIC REVIEWS, vol. 8, no. 8, JPN6026013610, 2018, pages 1 - 7, ISSN: 0005834534 * |
| LIMEGROVER, C. S. ET AL.: "Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson’s patient brain-deriv", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 99, no. 4, JPN6026013614, 22 January 2021 (2021-01-22), pages 1161 - 1176, ISSN: 0005834536 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117355525A (zh) | 2024-01-05 |
| AU2022239497A1 (en) | 2023-09-21 |
| EP4308565A4 (en) | 2025-01-01 |
| WO2022197885A1 (en) | 2022-09-22 |
| KR20230159546A (ko) | 2023-11-21 |
| MX2023010831A (es) | 2023-09-27 |
| US20240165077A1 (en) | 2024-05-23 |
| US20260166006A1 (en) | 2026-06-18 |
| IL306063A (en) | 2023-11-01 |
| CA3212092A1 (en) | 2022-09-22 |
| EP4308565A1 (en) | 2024-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2911664B1 (en) | Combination therapies for the treatment of alzheimer's disease and related disorders | |
| US20240165077A1 (en) | Compositions and methods for treating neurologic diseases | |
| US20240009168A1 (en) | Compositions for treating dry age-related macular degeneration (amd) | |
| US11981636B2 (en) | Compositions for treating neurodegenerative diseases | |
| TW201412325A (zh) | 用於治療患有青光眼及其他退化性眼疾之人類視力喪失的間隔醫療 | |
| JP2022542645A (ja) | 眼障害の治療のための化合物 | |
| EP2412705B1 (en) | Novel therapeutic agent for cognitive impairment | |
| CN117797134A (zh) | 一种4-tmap治疗或缓解抑郁症的用途 | |
| WO2025122753A2 (en) | Compositions and methods for the treatment of niemann-pick disease | |
| KR102857195B1 (ko) | (r)-2-(4-(1-하이드록시프로판-2-일)페닐)이소인돌린-1-온 화합물 및 이의 용도 | |
| RU2792562C2 (ru) | Композиции для лечения нейродегенеративных заболеваний | |
| CA3061787C (en) | Compositions for treating neurodegenerative diseases | |
| WO2026030341A1 (en) | Zervimesine for treating neurodegenerative disease | |
| EA053296B1 (ru) | Конъюгаты простого эфира фосфолипида в качестве носителей лекарственного средства для нацеливания на рак | |
| HK40016881A (en) | Combination therapies for the treatment of alzheimer's disease and related disorders | |
| HK1212603B (en) | Combination therapies for the treatment of alzheimer's disease and related disorders | |
| HK1213494B (en) | Combination therapies for the treatment of alzheimer's disease and related disorders | |
| HK1165792A (en) | Novel therapeutic agent for cognitive impairment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250315 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250315 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260407 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260702 |